ReviewFrontiers in bioengineering and biotechnology2019
At the Intersection of Biomaterials and Gene Therapy: Progress in Non-viral Delivery of Nucleic Acids.
Review in Frontiers in bioengineering and biotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Progress and prospect of minicircle as a minimized non-viral DNA vector in gene therapy and regenerative medicine.Molecular therapy. Nucleic acids · 2025Review
- 8-Oxo-7,8-dihydropurines as Building Blocks to Enhance the Selectivity of an RNA Aptamer for Aminoglycosides.ACS chemical biology · 2025Article
- Gene Augmentation Techniques to Stimulate Wound Healing Process: Progress and Prospects.Current gene therapy · 2025Review
- Biomaterials for Cell Manufacturing.ACS macro letters · 2024Article
- mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles.International journal of molecular sciences · 2024Review
- Electrospun Scaffolds Enriched with Nanoparticle-Associated DNA: General Properties, DNA Release and Cell Transfection.Polymers · 2023Article
- Non-viral gene delivery to human mesenchymal stem cells: a practical guide towards cell engineering.Journal of biological engineering · 2023Review
- Nanoparticles and cytokine response.Frontiers in bioengineering and biotechnology · 2023Review
- Advances in Aptamers-Based Applications in Breast Cancer: Drug Delivery, Therapeutics, and Diagnostics.International journal of molecular sciences · 2022Review
- G-Quadruplex Linked DNA Guides Selective Transfection into Nucleolin-Overexpressing Cancer Cells.Pharmaceutics · 2022Article
- Gene therapy to enhance angiogenesis in chronic wounds.Molecular therapy. Nucleic acids · 2022Review
- Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects.Journal of nanobiotechnology · 2022Review
- Peptide-Assisted Nucleic Acid Delivery Systems on the Rise.International journal of molecular sciences · 2021Review
- Sample preparation strategies for efficient correlation of 3D SIM and soft X-ray tomography data at cryogenic temperatures.Nature protocols · 2021Article
- MiRNAs and Muscle Regeneration: Therapeutic Targets in Duchenne Muscular Dystrophy.International journal of molecular sciences · 2021Review
- Hydrogel-Based Localized Nonviral Gene Delivery in Regenerative Medicine Approaches-An Overview.Pharmaceutics · 2020Review
- Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA.Frontiers in bioengineering and biotechnology · 2020Article
- Insights on the DNA Stability in Aqueous Solutions of Ionic Liquids.Frontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomaterials play a critical role in technologies intended to deliver therapeutic agents in clinical settings. Recent explosion of our understanding of how cells utilize nucleic acids has garnered excitement to develop a range of older (e.g., antisense oligonucleotides, plasmid DNA and transposons) and emerging (e.g., short interfering RNA, messenger RNA and non-coding RNAs) nucleic acid agents for therapy of a wide range of diseases. This review will summarize biomaterials-centered advances to undertake effective utilization of nucleic acids for therapeutic purposes. We first review various types of nucleic acids and their unique abilities to deliver a range of clinical outcomes. Using recent advances in T-cell based therapy as a case in point, we summarize various possibilities for utilizing biomaterials to make an impact in this exciting therapeutic intervention technology, with the belief that this modality will serve as a therapeutic paradigm for other types of cellular therapies in the near future. We subsequently focus on contributions of biomaterials in emerging nucleic acid technologies, specifically focusing on the design of intelligent nanoparticles, deployment of mRNA as an alternative to plasmid DNA, long-acting (integrating) expression systems, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.